Profound Total Current Liabilities from 2010 to 2026
| PROF Stock | USD 5.61 0.20 3.70% |
Total Current Liabilities | First Reported 2014-09-30 | Previous Quarter 9.9 M | Current Value 8.3 M | Quarterly Volatility 2.5 M |
Macro event markers
Financial statement trends for Profound Medical provide structured context on operating performance and capital structure. The series highlights drivers like Depreciation And Amortization of 1.1 M, Interest Expense of 737.9 K or Selling General Administrative of 27.9 M and ratios such as Price To Sales Ratio of 13.75, Dividend Yield of 0.0 or PTB Ratio of 3.8, complementing Profound Medical Valuation and Volatility.
Profound | Total Current Liabilities | Build AI portfolio with Profound Stock |
The Total Current Liabilities trend for Profound Medical Corp offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Profound Medical is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Profound Medical's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Profound Medical Corp over the last few years. Total Current Liabilities is an item on Profound Medical balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Profound Medical Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Profound Medical's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Profound Medical's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Profound Total Current Liabilities Regression Statistics
| Arithmetic Mean | 3,978,945 | |
| Geometric Mean | 1,586,095 | |
| Coefficient Of Variation | 79.72 | |
| Mean Deviation | 2,675,921 | |
| Median | 4,185,000 | |
| Standard Deviation | 3,172,118 | |
| Sample Variance | 10.1T | |
| Range | 8.4M | |
| R-Value | 0.78 | |
| Mean Square Error | 4.2T | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | 489,976 | |
| Total Sum of Squares | 161T |
Profound Total Current Liabilities History
About Profound Medical Corp
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada. Profound Medical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 146 people. This stock section frames Profound Medical within its peer set and highlights how fundamentals align with price behavior. Current metrics include P/B of 6.13, profit margin of -2.64%. Profound Medical has a market cap of 196.34 M, ROE of -67.11%. 
Michael Smolkin ยท Member of Macroaxis Board of Directors
Methodology
Unless otherwise specified, financial data for Profound Medical Corp is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Profound (USA Stocks:PROF) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Profound Medical Corp may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Profound Stock is Curated By:
Michael Smolkin ยท Member of Macroaxis Board of DirectorsCurrently Active Assets on Macroaxis
More Resources for Profound Stock Analysis
A comprehensive view of Profound Medical Corp starts with financial statements and ratio context. Ratios and trend metrics help frame Profound Medical's operating context. Highlighted below are reports that provide context for Profound Medical Corp Stock:Profound Medical Correlation provides competitor comparison context for Profound Medical. This supports competitive context. Analysis related to Profound Medical should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Earnings Share -1.32 | Revenue Per Share | Quarterly Revenue Growth 0.431 | Return On Assets | Return On Equity |
Understanding Profound Medical Corp includes distinguishing between market value and book value, where book value reflects Profound accounting equity. Profound Medical's market capitalization is 196.34 M. With a P/B ratio of 6.13, the market values Profound Medical well above its book equity. Enterprise value stands at 174.69 M. Intrinsic value is an estimate of what Profound Medical's fundamentals imply, and it may differ from market and book figures. Analytical frameworks help compare those viewpoints.
The concept of value for Profound Medical differs from its quoted price, since each reflects a different lens. For Profound Medical, key inputs include a P/B ratio of 6.13, a profit margin of -2.64%, ROE of -67.11%, and revenue of 16.1 M. Market price reflects the current exchange level formed by active bids and offers.